Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
This review surveys the basic pharmacology of angiotensin II receptors and their antagonism; reviews the existing clinical experience with losartan, the first approved nonpeptide angiotensin II antagonist; suggests other possible clinical areas for angiotensin II receptor antagonism; and compares angiotensin-converting enzyme inhibition with angiotensin receptor antagonism.
Triggle
D J
DJ
School of Pharmacy, State University of New York at Buffalo, New York, USA.
D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006168:Guinea Pigs; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D019808:Losartan; D051381:Rats; D011945:Receptors, Angiotensin / Q000145:classification; D012084:Renin-Angiotensin System / Q000187:drug effects; D013777:Tetrazoles / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; C066026:losartan carboxylic acid; D019808:Losartan